443290-32-2

Basic information

• Product Name: N-(3-AMINOPHENYL)-2-CHLOROBENZAMIDE
• Synonyms: AKOS BB-8149;ASISCHEM T31114;ART-CHEM-BB B025195;LABOTEST-BB LT00251075;N-(3-AMINOPHENYL)-2-CHLOROBENZAMIDE
• CAS NO: 443290-32-2
• Molecular Formula: C13H11ClN2O
• Molecular Weight: 246.69
• Mol File: 443290-32-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3-AMINOPHENYL)-2-CHLOROBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-AMINOPHENYL)-2-CHLOROBENZAMIDE(443290-32-2)
• EPA Substance Registry System: N-(3-AMINOPHENYL)-2-CHLOROBENZAMIDE(443290-32-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 443290-32-2(Hazardous Substances Data)

Upstream product

• 108-45-2 m-phenylenediamine 
• 609-65-4 o-chlorobenzoyl chloride 
• 99-09-2 3-nitro-aniline 
• 90665-30-8 N-(o-chlorobenzoyl)-3-nitroaniline 

Downstream Products

• 330821-81-3 C₂₀H₁₅ClN₂O₂ 
• 59517-27-0 2-Chloro-N-(3-propionylamino-phenyl)-benzamide 

Relevant articles and documents

Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking

Herein, we embarked on a structural optimization campaign aiming at the discovery of novel anticancer agents with our previously reported XL-6f as a lead compound. A library of 23 compounds has been synthesized based on the highly conserved active site of VEGFR-2. Several title compounds exhibited selective inhibitory activities against VEGFR-2, which also displayed selective anti-proliferation potency against HepG2 cell. All synthesized compounds were evaluated for anti-angiogenesis capability. Compound 7o showed the most potent anti-angiogenesis ability, the efficient cytotoxic activities (in vitro against HUVEC and HepG2 cell lines with IC50 values of 0.58 and 0.23 μM, respectively). The molecular docking analysis revealed 7o is a Type-II inhibitor of VEGFR-2 kinase. In general, these results indicated these arylamide-5-anilinoquinazoline-8-nitro derivatives are promising inhibitors of VEGFR-2 for the potential treatment of anti-angiogenesis.

Acylthiourea, acylurea, and acylguanidine derivatives with potent Hedgehog inhibiting activity

The Smoothened (Smo) receptor is the major transducer of the Hedgehog (Hh) signaling pathway. On the basis of the structure of the acylthiourea Smo antagonist (MRT-10), a number of different series of analogous compounds were prepared by ligand-based structural optimization. The acylthioureas, originally identified as actives, were converted into the corresponding acylureas or acylguanidines. In each series, similar structural trends delivered potent compounds with IC50 values in the nanomolar range with respect to the inhibition of the Hh signaling pathway in various cell-based assays and of BODIPY-cyclopamine binding to human Smo. The similarity of their biological activities, in spite of discrete structural differences, may reveal the existence of hydrogen-bonding interactions between the ligands and the receptor pocket. Biological potency of compounds 61, 72, and 86 (MRT-83) were comparable to those of the clinical candidate GDC-0449. These findings suggest that these original molecules will help delineate Smo and Hh functions and can be developed as potential anticancer agents.

SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS

ABSTRACT The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c= or N=; R1 is C2-C6 alkyl, substituted C2-C6/